Favorable News Coverage Somewhat Unlikely to Impact Onconova Therapeutics (ONTX) Share Price
Press coverage about Onconova Therapeutics (NASDAQ:ONTX) has trended positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Onconova Therapeutics earned a coverage optimism score of 0.29 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 47.4865339674639 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of brokerages have recently weighed in on ONTX. Maxim Group set a $6.00 price objective on shares of Onconova Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 6th. Dawson James reissued a “buy” rating on shares of Onconova Therapeutics in a report on Tuesday, July 25th. Finally, ValuEngine raised shares of Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday.
Shares of Onconova Therapeutics (ONTX) traded up 3.09% during midday trading on Friday, hitting $1.67. 10,227 shares of the stock were exchanged. The stock has a 50 day moving average price of $1.86 and a 200-day moving average price of $2.27. The company’s market cap is $16.45 million. Onconova Therapeutics has a 12 month low of $1.51 and a 12 month high of $3.88.
Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.43. Onconova Therapeutics had a negative net margin of 762.13% and a negative return on equity of 558.97%. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.25 million. On average, analysts predict that Onconova Therapeutics will post ($2.92) EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/favorable-news-coverage-somewhat-unlikely-to-impact-onconova-therapeutics-ontx-share-price/1538277.html.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.